Clinical Programs

Press Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Dec 9, 2015
    Prof. Mechoulam, the “father of medical cannabis” is one of the industry’s pioneers, and was the first to describe the “entourage effect” which serves as basis for one of the Company’s technologies

    Therapix Biosciences announces the appointment of Prof. Raphael Mechoulam as member of the Company’s scientific advisory board, further to the decision to focus the Company’s business strategy...

  • Dec 9, 2015
    Dr. Elran Haber was appointed CEO of the Company and Doron Ben Ami was appointed VP Strategy of the Company

    Therapix, a company engaged in the development of drugs based on the active compounds in cannabis, announces today of key appointments to the Company’s management. Dr. Elran Haber was appointed...

  • Oct 26, 2015
    The investment agreements include a private placement to investors at NIS 1.05 per share, for a total of approx. NIS 3.3 million. In addition, the investors signed agreements for the exercise of options granted in the context of the Dekel transaction, for approx. NIS 2.3 million.

    Therapix, a company engaged in the development of cannabinoid-based drugs, announces today that it had entered into a series of investment agreements for a total of approx. NIS 5.6 million. The...

  • Aug 16, 2015

    The Company wishes to update, in respect of the Company’s investment agreement in LaraPharm Ltd., that further to discussions recently held between the Company and LaraPharm’s management, the...

  • Aug 15, 2015
    The Company and Dekel Pharmaceuticals Ltd. ("Dekel") have signed a definitive exclusive royalty baring license agreement regarding Dekel's technology, IPs and knowhow. The Company granted Dekel an option for investing in the Company at predefined terms. The agreement was approved by the ISA and TASE.

    The Entourage Effect Cannabinoids are a diverse group of chemical compounds that operate on specific receptors in the body (CB1 and CB2). This family includes molecules that are derived from the...

Show 5102550100 per page